Your browser is no longer supported. Please, upgrade your browser.
IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own0.10% Shs Outstand204.84M Perf Week-18.66%
Market Cap1.24B Forward P/E- EPS next Y-0.86 Insider Trans0.00% Shs Float171.12M Perf Month-14.74%
Income-70.70M PEG- EPS next Q-1.86 Inst Own83.70% Short Float7.61% Perf Quarter-0.17%
Sales127.70M P/S9.75 EPS this Y64.10% Inst Trans-0.07% Short Ratio3.18 Perf Half Y2.10%
Book/sh0.38 P/B15.37 EPS next Y-26.50% ROA-21.80% Target Price10.94 Perf Year-25.89%
Cash/sh1.15 P/C5.06 EPS next 5Y- ROE-85.90% 52W Range4.72 - 10.88 Perf YTD-21.29%
Dividend- P/FCF- EPS past 5Y31.50% ROI-24.40% 52W High-45.63% Beta1.29
Dividend %- Quick Ratio2.40 Sales past 5Y17.10% Gross Margin- 52W Low25.19% ATR0.40
Employees79 Current Ratio2.40 Sales Q/Q-49.50% Oper. Margin-42.30% RSI (14)36.36 Volatility6.32% 5.60%
OptionableYes Debt/Eq0.00 EPS Q/Q-42.20% Profit Margin-55.40% Rel Volume0.18 Prev Close5.84
ShortableYes LT Debt/Eq0.00 EarningsOct 29 BMO Payout- Avg Volume4.09M Price5.91
Recom1.90 SMA20-15.78% SMA50-8.25% SMA200-6.39% Volume72,527 Change1.28%
Dec-01-21Upgrade Jefferies Hold → Buy $7 → $12
Oct-26-20Resumed H.C. Wainwright Buy $11
Oct-02-20Upgrade Guggenheim Neutral → Buy $14
Sep-29-20Resumed JP Morgan Neutral
Dec-17-19Reiterated H.C. Wainwright Buy $5 → $9
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
May-15-19Downgrade Guggenheim Buy → Neutral
May-06-19Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19Upgrade Cowen Market Perform → Outperform
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Jan-06-22 04:34PM  
Jan-05-22 01:38PM  
Jan-04-22 10:00AM  
Jan-03-22 10:36PM  
04:30PM  
Dec-31-21 06:44AM  
Dec-29-21 04:30PM  
Dec-14-21 09:01AM  
Dec-12-21 09:30AM  
Dec-11-21 10:19PM  
06:00AM  
Dec-06-21 04:01PM  
Dec-02-21 12:00AM  
Dec-01-21 01:25PM  
10:06AM  
09:22AM  
Nov-30-21 04:33PM  
04:01PM  
12:48PM  
08:15AM  
06:30AM  
05:55AM  
02:11AM  
Nov-24-21 04:30PM  
Nov-17-21 04:01PM  
Nov-16-21 04:30PM  
06:30AM  
Nov-11-21 10:58AM  
Nov-04-21 09:00AM  
Nov-01-21 08:03PM  
04:04PM  
12:24PM  
09:11AM  
Oct-29-21 05:00PM  
07:45AM  
06:30AM  
Oct-22-21 03:00PM  
Oct-19-21 12:31PM  
Oct-14-21 04:01PM  
Oct-01-21 04:30PM  
Sep-22-21 04:01PM  
Aug-02-21 04:30PM  
09:19AM  
Jul-30-21 11:30AM  
07:55AM  
06:30AM  
Jul-23-21 03:00PM  
Jul-15-21 04:01PM  
Jul-13-21 08:38AM  
Jul-01-21 04:30PM  
Jun-10-21 02:09AM  
Jun-09-21 11:30AM  
Jun-01-21 04:30PM  
May-20-21 04:30PM  
May-19-21 05:00PM  
May-10-21 12:00PM  
11:03AM  
07:45AM  
06:30AM  
06:15AM  
May-03-21 04:30PM  
Apr-26-21 04:01PM  
Apr-20-21 10:13AM  
Apr-16-21 04:41AM  
Apr-10-21 08:30AM  
Apr-01-21 04:30PM  
Mar-14-21 11:30AM  
Mar-01-21 04:30PM  
Feb-24-21 04:30PM  
Feb-14-21 11:25PM  
Feb-13-21 03:51AM  
Feb-12-21 11:30AM  
11:30AM  
08:44AM  
07:45AM  
06:30AM  
06:15AM  
04:37AM  
Feb-11-21 04:30PM  
10:04AM  
Feb-05-21 12:30PM  
Feb-01-21 04:30PM  
Jan-29-21 04:01PM  
Jan-04-21 04:30PM  
Dec-30-20 04:30PM  
Dec-26-20 03:58AM  
Dec-16-20 03:20PM  
Dec-06-20 11:30AM  
Dec-05-20 03:01PM  
Dec-01-20 04:30PM  
Nov-30-20 04:30PM  
Nov-18-20 04:30PM  
Nov-11-20 06:33AM  
Nov-10-20 06:23AM  
Nov-09-20 09:56AM  
Nov-06-20 12:30PM  
07:52AM  
07:45AM  
06:30AM  
06:00AM  
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL DEAN JDirectorSep 03Option Exercise3.8783,000321,40093,000Sep 03 04:06 PM